Radiopharm Theranostics

RADX

The current Radiopharm Theranostics (RADX) market capitalization is approximately $52.22M, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, Radiopharm Theranostics's market cap fluctuates with changes in its share price and share count. Last updated: March 7, 2026 at 7:01 PM Eastern Time

In the most recently reported quarter, Radiopharm Theranostics (RADX) generated A$3.10M in revenue, representing a +154.52% year over year change. For the next quarter, analyst consensus currently expects revenue of approximately A$0.00, implying an expected -100.00% year over year change. Quarterly revenue results and expectations reflect underlying demand trends, pricing dynamics, product or service mix, seasonality, and broader macroeconomic conditions. Actual results may differ from consensus estimates as new information becomes available. Last updated: April 2, 2026 at 12:48 AM Eastern Time

In the most recently reported fiscal year, Radiopharm Theranostics (RADX) generated net income of A$-38.16M, compared with A$-32.56M in the prior fiscal year, representing a -17.20% year over year change. For the upcoming fiscal year, analyst consensus currently estimates net income of A$-47.34M. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions. Last updated: April 2, 2026 at 12:48 AM Eastern Time

According to its latest quarterly filing, Radiopharm Theranostics (RADX) reported EBITDA of A$-12.47M, representing a -36.34% year over year change. EBITDA is a non-GAAP measure and does not account for depreciation, amortization, interest expense, taxes, or capital expenditures. As a result, it should be considered alongside other financial metrics when assessing operating performance. Actual results may differ from estimates as company-specific or macroeconomic conditions evolve. Last updated: April 2, 2026 at 12:48 AM Eastern Time

Based on the latest available data, Radiopharm Theranostics (RADX) is currently trading at a last twelve months (LTM) P/E ratio of -1.13x. The P/E ratio reflects how much investors are willing to pay today for a dollar of earnings and can vary meaningfully over time due to changes in profitability, growth expectations, margin outlook, and earnings volatility. Last updated: April 2, 2026 at 4:59 PM Eastern Time

In the most recently reported quarter, Radiopharm Theranostics (RADX) revenue was A$3.10M, compared with analyst consensus expectations of A$0.00. Earnings per share (EPS) for the quarter were A$-0.01, compared with consensus estimates of A$-0.01, resulting in an +47.50% EPS surprise. Revenue and EPS surprises may be positive or negative and can influence near-term stock performance depending on expectations, forward guidance, and broader market and sector conditions. For a detailed history of analyst expectations versus reported results, view the full estimates vs. actuals track record here: 👉 Estimates vs. Actuals Last updated: April 2, 2026 at 12:48 AM Eastern Time

Radiopharm Theranostics (RADX) does not currently pay a dividend. Over the last twelve months (LTM), the company paid $0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future. Last updated: April 2, 2026 at 12:48 AM Eastern Time

Analyst assessments of whether Radiopharm Theranostics (RADX) consensus price target is overvalued or undervalued are generally expressed relative to consensus valuation frameworks and price targets, rather than as an absolute judgment.Current share price: $4.40Consensus price target: $17.65Implied return: +253.74% An implied return above current levels indicates that, on average, analysts view the stock as trading below their estimated fair value. Conversely, an implied return below current levels suggests the stock may be fully valued or priced above consensus expectations. This content is for informational purposes only and does not constitute investment advice. Last updated: April 2, 2026 at 4:59 PM Eastern Time

Based on the latest available analyst coverage, Radiopharm Theranostics (RADX) currently carries a Buy consensus rating. Analysts' average RADX price target is $17.65. Relative to the current share price of $4.40, this suggests a potential price change of approximately +253.74%. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: April 2, 2026 at 4:59 PM Eastern Time

Like other publicly traded stocks, Radiopharm Theranostics (RADX) shares are bought and sold on stock exchanges such as ASX and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for Radiopharm Theranostics (RADX) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add RADX to your watchlist.

Radiopharm Theranostics trades under the ticker symbol RADX on the ASX stock exchange. The ticker RADX is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

As of the most recently reported period, Radiopharm Theranostics (RADX) employs approximately 14 people worldwide. Reported employee figures may fluctuate over time due to hiring activity, restructuring, automation initiatives, or changes in business strategy. Headcount data is typically disclosed in company filings and reflects full-time employees unless otherwise stated. Last updated: March 7, 2026 at 7:01 PM Eastern Time

Radiopharm Theranostics (RADX) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest Radiopharm Theranostics (RADX) stock peers based on overlapping products, services, and competitive dynamics:BioLineRx (BLRX)Prestige BioPharma (A950210)Curis (CRIS)Prelude Therapeutics (PRLD)Janux Therapeutics (JANX)Perspective Therapeutics (CATX)Cell Biotech (A049960)Clover Biopharmaceuticals (2197)Amplia Therapeutics (ATX) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to Radiopharm Theranostics.